A French National Centre for Scientific Research (CNRS) researcher holds a test tube rack containing cells to be infected with Covid-19 during coronavirus vaccine research work inside the Pasteur Institute laboratories in Lille, France, March 9, 2020.
Adrienne Surprenant | Bloomberg | Getty Images
Johnson & Johnson is aiming to produce between 600 million and 900 million doses of its potential coronavirus vaccine by the end of the first quarter of 2021 if human trials scheduled to begin in September go as planned.
It plans to make 1 billion doses or more annually, J&J executives told investors during a post-earnings conference call on Tuesday.
The comments came shortly after the drugmaker raised its quarterly dividend and reported first-quarter financial results that beat Wall Street’s expectations.
The company also lowered its 2020 adjusted earnings forecast due to the coronavirus outbreak. It’s now expecting a range of $ 7.50 to $ 7.90 per share, from its prior estimate of $ 8.95 to $ 9.10 per share.
This is a developing story. Please check back for updates.